The Joint swings to Q2 FY26 profit of $653,000; revenue rises 14% to $15.2 million

Full-year guidance reiterated

The company reiterated 2026 guidance for system-wide sales of $519 million-$552 million, and consolidated adjusted EBITDA (non-GAAP) of $12.5 million-$13.5 million.

Sales trends and clinic count

System-wide sales fell 3.7% to $180 million, while comp sales improved 140 basis points versus Q1 to -2.8%.

Clinic count totaled 941 at June 30; the company opened five clinics, closed seven, and refranchised 29 during the quarter.

Q2 results improve on higher revenue

The Joint Corp. posted Q2 net income of $653,000, up from $93,000 a year earlier, as revenue rose 14% to $15.2 million.

Adjusted EBITDA (non-GAAP) from continuing operations rose to $1.5 million from $88,000, while cash flow from operating activities more than doubled to .

Full-year guidance reiterated

Sales trends and clinic count

Q2 results improve on higher revenue

Related News

Oculis Q2 2026 loss narrows on CHF 12.1 million warrant valuation gain, FX swing to profit

Canada's CAPREIT Q2 revenue slightly beats driven by increased monthly rents on lease renewals

Ready Capital posts Q2 loss; CEO says earnings pressure narrowing

Sources

The Joint swings to Q2 FY26 profit of $653,000; revenue rises 14% to $15.2 million

Research Frontiers' Q2 fee income declines

WEX COO, American Payments & Mobility Carlos Carriedo sells 1,075 shares for $199,950